Fusen Pharmaceutical Receives Regulatory Approval for Glucosamine Sulfate Capsule, Targeting Osteoarthritis Market

Key Highlights

• Regulatory Approval: Fusen Pharmaceutical Company Limited (“Fusen Pharmaceutical”, Stock Code: 1652) announced that its wholly-owned subsidiary, Henan Fusen Pharmaceutical Company Limited, has secured approval from the National Medical Products Administration (NMPA) of China to market its new “Glucosamine Sulfate Capsule” (trademark: Shuhuitong 舒匯通) for the treatment of primary and secondary osteoarthritis.
• Product Overview: The Glucosamine Sulfate Capsule contains natural amino monosaccharides, essential for synthesizing human articular cartilage matrix. This drug serves as a protective agent for articular cartilage, capable of alleviating joint pain, enhancing joint function, repairing cartilage, and facilitating the reconstruction of the cartilage matrix.
• Therapeutic Value: The capsule addresses both short-term pain relief and long-term maintenance of joint function, meeting critical therapeutic needs for osteoarthritis patients. The market for such products is expanding due to China’s aging population and the rising prevalence of joint diseases.
• Market Data: According to Menet, sales revenue for Glucosamine Sulfate Capsules in China exceeded RMB 850 million in 2024, with a robust year-on-year growth rate of 25.28% for 2024 and 26.84% in the first three quarters of 2025.
• Reimbursement Status: Glucosamine Sulfate Capsule is classified as a Class B drug under the “National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalog (2025 Edition),” positioning it for enhanced accessibility and sustained demand.
• Strategic Importance: The approval strengthens Fusen Pharmaceutical’s product pipeline, marking a significant step in its expansion into the osteoarthritis therapeutic segment.

Investor Insights and Shareholder Considerations

• Potential Share Price Catalyst: The regulatory approval of Glucosamine Sulfate Capsule could significantly enhance the revenue prospects and market share of Fusen Pharmaceutical, given the strong growth trends in the osteoarthritis treatment market and the drug’s inclusion in national reimbursement schemes.
• Market Opportunity: Osteoarthritis prevalence in China is growing not only among the elderly but also younger generations due to lifestyle changes, obesity, and increased joint strain. This trend ensures a rising and sustained demand for effective osteoarthritis therapies, providing a solid commercial foundation for the new product.
• Policy Support: The product is expected to benefit from government initiatives under the “Healthy China Strategy” and the “15th Five-Year Plan,” both of which emphasize public health and the management of chronic diseases.
• Pipeline Expansion: The Glucosamine Sulfate Capsule further diversifies and strengthens Fusen Pharmaceutical’s product lineup in the high-growth therapeutic area of osteoarthritis, potentially enhancing long-term shareholder value.

Management Commentary

“The approval of Glucosamine Sulfate Capsule marks a solid step forward for Fusen Pharmaceutical in the therapeutic area of osteoarthritis and will provide more therapeutic options for patients suffering from osteoarthritis,” said Mr. Cao Zhiming, Chairman and Executive Director of Fusen Pharmaceutical Company Limited.

Leadership and Governance

As of the announcement date, the Board includes Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, and Ms. Meng Qingfen as executive directors, with Mr. Lee Kwok Tung Louis, Dr. To Kit Wa, and Mr. Yu Ho Ming serving as independent non-executive directors.

Conclusion

The launch approval for Glucosamine Sulfate Capsule is a noteworthy development for Fusen Pharmaceutical, potentially driving substantial revenue growth and market expansion. The positive market fundamentals, policy support, and inclusion in key reimbursement lists position this product as a possible catalyst for the company’s share price and long-term value creation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisors before making investment decisions. The author and publisher are not liable for any losses arising from reliance on the information provided above.

View FUSEN PHARM Historical chart here